临床荟萃

• 荟萃分析 • 上一篇    下一篇

XRCC1多态性与胰腺癌发病风险的meta分析

  

  1. 1. 四川护理职业学院  药学与检验系,四川 成都 610100;2. 川北医学院附属医院  检验科,四川 南充 637000
  • 出版日期:2017-08-05 发布日期:2017-08-10
  • 通讯作者: 通信作者:苏国明,Email:guomingsu77@163.com

Association between XRCC1 polymorphisms and pancreatic cancer risk: a metaanalysis

  1. 1. Department of Pharmacy and Laboratory, Sichuan Nursing Vocational College, Chengdu 610100, China;
    2. Medical Laboratory, the Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,China
  • Online:2017-08-05 Published:2017-08-10
  • Contact: Corresponding author:Su Guoming,Email:guomingsu77@163.com

摘要: 目的  本文旨在系统评价X线修复交叉互补基因1(Xray repair crosscomplementating group 1, XRCC1)的单核苷酸多态性(single nucleotide polymorphisms, SNP)与胰腺癌发病风险的相关性。方法  计算机检索数据库PubMed、Embase、the Cochrane Library、Web of Science、中国生物医学文献数据库(CBM)、万方数据库、中国期刊全文数据库(CNKI),按照纳入与排除标准筛选文献,对研究结果进行meta分析,评价发表偏倚并进行敏感性分析。结果  共纳入8篇病例-对照研究,合并结果显示:XRCC1上的Arg399Gln(rs25487 G>A)突变和Arg194Trp (rs1799782 C>T)突变与胰腺癌发病风险之间的关联差异无统计学意义;XRCC1上的Arg280His(rs25489 G>A)突变与胰腺癌的发病风险密切相关(A vs G: OR=0.743,95%CI=0.576~0.958,P=0.022; GA vs GG: OR=0.701,95%CI=0.525~0.936,P=0.016; AA+GA vs GG: OR=0.710,95%CI=0.537~0.939,P=0.016);Egger检验显示不存在发表偏倚(P>0.05);敏感分析逐个剔除研究后meta分析结果受单个研究的影响较小。结论  本研究表明XRCC1上的Arg399Gln (rs25487 G>A)突变和Arg194Trp (rs1799782 C>T)突变与胰腺癌的发病风险无明显相关性;XRCC1上的Arg280His (rs25489 G>A)突变可能与胰腺癌的发病风险有关联。

关键词: 胰腺肿瘤;癌, 基因;meta分析

Abstract: Objective  To systematically evaluate the association between XRCC1 single nucleotide polymorphisms and pancreatic cancer risk. Methods  An electronic search of PubMed, Embase, the Cochrane Library, Web of Science, CBM, Wanfang Data and CNKI  database were conducted. Studies were identified with the criteria for inclusion and exclusion for metaanalysis. Publication bias was examined and sensitivity analysis was also performed. Results  A total of eight  casecontrol  studies were included in the metaanalysis. The combined results showed that there was no significant association between XRCC1 Arg399Gln (rs25487 G>A) mutant and Arg194Trp (rs1799782 C>T)  mutant and pancreatic cancer risk. There was significant association between XRCC1 Arg280His (rs25489 G>A) mutant and pancreatic cancer risk (A vs G: OR=0.743,95%CI=0.5760.958,P=0.022; GA vs GG: OR=0.701,95%CI=0.5250.936,P=0.016; AA+GA vs GG: OR=0.710,95%CI=0.5370.939,P=0.016). Egger linear regression test revealed that there was no publication bias (P>0.05). Sensitivity analysis showed that the results were robust to the removal of each individual trial from the metaanalysis.Conclusion  This study showed that XRCC1 Arg399Gln (rs25487 G>A)  mutant  and Arg194Trp (rs1799782 C>T)mutant had no significant correlation with the risk of pancreatic cancer. XRCC1 Arg280His (rs25489 G>A) mutant might be associated with the risk of pancreatic cancer.

Key words: pancreatic neoplasms, oncogenes, metaanalysis